Complex differential spectral interferometry

Information

  • Research Project
  • 7110658
  • ApplicationId
    7110658
  • Core Project Number
    R44HL079781
  • Full Project Number
    2R44HL079781-02
  • Serial Number
    79781
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/15/2004 - 20 years ago
  • Project End Date
    2/28/2008 - 16 years ago
  • Program Officer Name
    EVANS, FRANK
  • Budget Start Date
    4/12/2006 - 18 years ago
  • Budget End Date
    2/28/2007 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    2
  • Suffix
  • Award Notice Date
    4/12/2006 - 18 years ago

Complex differential spectral interferometry

[unreadable] DESCRIPTION (provided by applicant): Summary. Atherosclerosis is indicated by the American Heart Association as a primary factor in three fourths of deaths resulting from cardiovascular disease. It is now recognized that many coronary events and strokes are caused by atherosclerotic plaques that rupture - vulnerable plaques. It is important that the cardiologist be able to assess the risk of plaque rupture when diagnosing and treating persons with atherosclerosis. Currently available imaging tools (angioscopy, MRI, intravascular ultrasound) do not provide the high spatial resolution needed for this application. We propose to develop a rapid, high resolution optical imaging method for imaging of venous and arterial structures that will aid in the diagnosis of atherosclerosis, specifically in identifying vulnerable plaques. The new technique, which we call complex differential spectral interferometry (CDSI), will be an important improvement to optical coherence tomography (OCT). It will provide video-rate cross-sectional imaging and will have higher dynamic range than standard time domain OCT. It will be fully compatible with fiber optics allowing incorporation into endoscopes, catheters and similar devices for in vivo applications. In Phase I, we achieved a breakthrough in the development of CDSI (also known as complex Fourier domain OCT). The newly developed version resolves the problem of the complex conjugate ambiguity (one of the main drawbacks of Fourier domain OCT) in an elegant and exceptionally efficient way, which provides a two-fold increase of the maximum imaging depth. In Phase II, the new technique will be used with a novel detector, recently designed and built at Southwest Sciences. The proposed technology takes full advantage of parallel detection inherent in CDSI allowing the greater dynamic range and sensitivity of Fourier domain OCT to be realized. Relevance. Cardiovascular disease affects over 61 million Americans and is the leading cause of death in the US. The major risk is associated with atherosclerotic plaques that rupture - vulnerable plaques, - which are difficult to diagnose with currently available methods. The proposed technology will aid in the diagnosis of vulnerable atherosclerotic plaques, thus providing important information for the cardiologist making risk assessments and choosing the best course of treatment, ultimately, saving lives. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    406163
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:406163\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SOUTHWEST SCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SANTA FE
  • Organization State
    NM
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    87505
  • Organization District
    UNITED STATES